Legal status in the United States

Is Teriparatide legal?

Read at FDA, DEA and WADAPublished by PepVault

Teriparatide is FDA-approved (Forteo and Bonsity, first in 2002), is not a federally controlled substance, and is not named on WADA’s Prohibited List, as of November 18, 2026.

Teriparatide at a glance

CheckStatus, read Nov 18, 2026
FDA approvalApproved (Forteo, 2002)
CompoundingComponent of an approved drug (503A condition)
DEA scheduleNot controlled
Sport (WADA)Not named on the list

FDA approval

Teriparatide is FDA-approved for osteoporosis, as Forteo since 2002 (the earliest teriparatide approval date Drugs@FDA gives), as Bonsity since 2019, and as generic teriparatide injections. Drugs@FDA also lists an older teriparatide product, Parathar, as discontinued, without an approval date.

  • Forteo (injection)

    Approved for osteoporosis at high risk of fracture in women after menopause and in men, and osteoporosis caused by long-term steroid treatment. NDA 021318, first approved November 26, 2002.

  • Bonsity (injection)

    Approved for osteoporosis at high risk of fracture in women after menopause and in men, and osteoporosis caused by long-term steroid treatment. NDA 211939, first approved October 4, 2019.

A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Compounding

Teriparatide is the active ingredient of FDA-approved drugs (Forteo, Bonsity). FDA’s page on bulk drug substances gives three conditions under section 503A for a substance a pharmacy compounds from, and one of them is being a component of an FDA-approved drug product; the 503A and 503B bulks lists don’t name teriparatide.

The source: “Are components of FDA-approved drug products if an applicable USP or NF monograph does not exist”

DEA schedule

It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.

Sport (WADA)

The 2026 Prohibited List doesn’t name teriparatide or parathyroid hormone, and S0, the class for unapproved substances, doesn’t reach an approved drug.

What this means and doesn’t

This page reports what the agencies’ own pages said about Teriparatide in the United States when we read them on November 18, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.

It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.

Questions

  • Is Teriparatide FDA approved?

    Teriparatide is FDA-approved for osteoporosis, as Forteo since 2002 (the earliest teriparatide approval date Drugs@FDA gives), as Bonsity since 2019, and as generic teriparatide injections. Drugs@FDA also lists an older teriparatide product, Parathar, as discontinued, without an approval date.

  • Is Teriparatide a controlled substance?

    It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.

  • Is Teriparatide banned in sport?

    The 2026 Prohibited List doesn’t name teriparatide or parathyroid hormone, and S0, the class for unapproved substances, doesn’t reach an approved drug.

  • What does FDA say about compounding Teriparatide?

    Teriparatide is the active ingredient of FDA-approved drugs (Forteo, Bonsity). FDA’s page on bulk drug substances gives three conditions under section 503A for a substance a pharmacy compounds from, and one of them is being a component of an FDA-approved drug product; the 503A and 503B bulks lists don’t name teriparatide.

Read next

Track it in the app

PepVault for iPhone

Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo